[HTML][HTML] Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study
…, S Antinori, M Corbellino, M Galli… - The Lancet infectious …, 2020 - thelancet.com
Background COVID-19 is characterised by respiratory symptoms, which deteriorate into
respiratory failure in a substantial proportion of cases, requiring intensive care in up to a third of …
respiratory failure in a substantial proportion of cases, requiring intensive care in up to a third of …
[PDF][PDF] Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
…, S Carmichael, C Garzoni, J Nichols, M Galli… - Cell, 2021 - cell.com
SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging
vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-…
vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-…
Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study
…, G Rizzardini, S Antinori, M Galli - Clinical infectious …, 2020 - academic.oup.com
To the Editor—We read with interest the article by Wang et al [1] describing the clinical
features of 69 patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
features of 69 patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
[HTML][HTML] Remdesivir for 5 or 10 days in patients with severe Covid-19
…, R Montejano, CD Spinner, M Galli… - … England Journal of …, 2020 - Mass Medical Soc
Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro
and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods We …
and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods We …
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
…, MA Schmid, E Cameroni, A Riva, A Gabrieli, M Galli… - Science, 2020 - science.org
Efficient therapeutic options are needed to control the spread of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 …
syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 …
[HTML][HTML] Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection
…, P Santus, M Nebuloni, F Folli, GV Zuccotti, M Galli… - Nature …, 2021 - nature.com
Patients with coronavirus disease 2019 (COVID-19) are reported to have a greater prevalence
of hyperglycaemia. Cytokine release as a consequence of severe acute respiratory …
of hyperglycaemia. Cytokine release as a consequence of severe acute respiratory …
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
…, G Rizzardini, S Antinori, M Galli - Clinical and …, 2020 - europepmc.org
A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December
2019, and spread so rapidly that more than 200,000 cases have so far been reported …
2019, and spread so rapidly that more than 200,000 cases have so far been reported …
30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study
…, A Torre, L Meroni, S Rusconi, S Antinori, M Galli - Pharmacological …, 2020 - Elsevier
Italy was the first European country hit by the COVID-19 pandemic and has the highest number
of recorded COVID-19 deaths in Europe. This prospective cohort study of the correlates …
of recorded COVID-19 deaths in Europe. This prospective cohort study of the correlates …
Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control …
OBJECTIVE Poor outcomes have been reported in patients with type 2 diabetes and
coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic …
coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic …
[HTML][HTML] Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists
…, A Agostini, A Borgheresi, D Minorati, M Galli… - La radiologia …, 2020 - Springer
COVID-19 is an emerging infection caused by a novel coronavirus that is moving so rapidly
that on 30 January 2020 the World Health Organization declared the outbreak a Public …
that on 30 January 2020 the World Health Organization declared the outbreak a Public …
